Covidien reveals plans to move its manufacturing operations from Ireland to Thailand over the next two years, raising concerns the shift may leave up to 600 without jobs.
Covidien plc's (NYSE:COV) decision to shift one arm of its manufacturing operations to Thailand could leave more than one-third of its Irish workforce without jobs.
The Mansfield, Mass.-based med-tech giant plans to shift one of its manufacturing divisions in Ireland, which produces endo-tracheal tubes, to Thailand over the next two years.
The announcement raised the spectre of unemployment among the nation's press.
"A GLOBAL health care firm is moving one of its Irish manufacturing lines to Thailand, where companies can hire 15 workers for the price of one here," the Irish Independent reported.
The move also got the attention of the Irish Services Industrial Professional & Technical Union, which obtained assurances that no one would be laid in the near future.
"After meeting management we received assurances that there will be no redundancies at the company before the end of next summer," SIPTU organizer Frank Jones said in the union's press release. "This gives the union time to fully explore with the company all possibilities for maintaining the maximum number of jobs at the Covidien facility in Athlone."
The shift is being made in order to improve long-term viability in the Athlone operations, Covidien's VP of public relations Bruce Farmer told MassDevice via email, but the facility isn't going anywhere.
Cyberonics plans to buy back an additional 1 million shares before the end of fiscal 2015.
Ventana, a Roche Group subsidiary, won 510(k) clearance from the Food & Drug Administration for...
TYRX touts expanded 510(k) clearance for its AIGISRx N antibacterial envelope, now cleared for use...
Wall Street analysts find opportunities for savvy investors looking to take advantage of the fallout...